Pediatric chordomas are rare malignant neoplasms, and few data are available for optimizing therapeutic strategies and outcome. This study aimed at evaluating how best to manage them and to identify prognostic factors. This multicentric retrospective study included 40 children diagnosed with chordomas between 1966 and 2012. Clinical, radiological, and histopathological data, treatment modalities, and outcomes were reviewed. The median age was 12 years old. Most chordomas were histologically classical forms (45.5%) and were mostly located at the skull base (72.5%). The overall survival (OS) was 66.6% and 58.6%, and progression-free survival (PFS) was 55.7% and 52% at 5 and 10 years, respectively. Total resection was correlated with a better outcome (p ¼ 0.04 for OS and PFS, log-rank). A histopathological/immunohistochemical grading system recently crafted for adults was applied. In a multivariate analysis, it significantly correlated with outcome (PFS and OS, p ¼ 0.004), and the loss of BAF47 immunoexpression appeared to be a significant independent prognostic factor (PFS, p ¼ 0.033). We also identified clinical and histopathological parameters that correlated with prognosis. A new grading system combined with the quality of surgical resection could help classify patients to postpone radiotherapy in case of low risk. Targeted therapy and reirradiation at recurrence may be considered as potential therapeutic strategies.
INTRODUCTION
Chordomas are rare slow-growing malignant neoplasms believed to derive from notochordal remnants. They are most frequently located in the sacrococcygeal and in the skull base regions and particularly affect adults with a peak incidence at diagnosis between 50 and 60 years of age. Pediatric cases represent less than 5% of cases. Prognosis of these tumors essentially depends on their local evolution and their high capacity for recurrence. In terms of treatment, maximal surgical resection is the first step, followed by local irradiation, ideally with proton beam therapy. To date, chemotherapy is not considered as a standard treatment. Publications on pediatric chordomas are rare (250 cases in the literature) (1) . While age and extent of resection seem to influence the prognosis in children, no histopathological prognostic factors have yet been clearly identified (2) .
The aim of this multicentric retrospective study was to evaluate the clinical, neurosurgical, and immunohistochemical prognostic factors of 40 pediatric chordomas. The expression of potentially useful markers for targeted molecular therapies such as VEGF, EGFR, PTEN, pSTAT3, and the loss of BAF47 expression were also investigated.
MATERIALS AND METHODS

Patients
This multicentric and retrospective study included 40 patients younger than 18 years of age from 6 centers, with chordomas diagnosed between 1966 and 2012. Informed consent for the surgery and translational research program was obtained from the parents or guardian according to the IRB approved protocol (number DC-2009-955 for tumor banking). Clinical and radiological findings, the treatment type, and outcome (progression-free survival [PFS] and overall survival [OS] ) were analyzed by 2 pediatric neurosurgeons (K.B. and S.P.). The location of chordomas was reported as skull base (tumors of the clivus and of the first cervical vertebra) and non-skull base (tumors from the second cervical vertebra to the sacrum). The quality of surgical resection was assessed from CT and MR scans when available or from surgery, hospitalization, or radiology reports when imaging was not available. The diagnosis of chordoma was based on histopathology, confirmed by Brachyury immunopositivity.
Histopathological Review
Central pathology review was performed by 2 neuropathologists (P.V. and A.T-E.). Tumors were subtyped into welldifferentiated chordomas (classical, chondroid, or mixed subtypes) and poorly differentiated chordomas, as previously defined (2) . Histopathological parameters (nuclear pleomorphism, prominent nucleoli, apoptosis, necrosis, hemorrhage, inflammatory cell infiltrates, and mitotic activity) were evaluated as in adult series (2) .
Immunohistochemistry
Immunohistochemical studies were performed using antibodies directed against Ki67 (clone K2; Zytomed, Berlin, Germany, 1:400), p53 (clone Do-7; Dako, Santa Clara, CA, 1:200), E-cadherin (clone EP700Y; Cell Marque, Rocklin, CA, 1:100), EGFR (clone 3C6; Ventana Medical Systems, Tucson, AZ, prediluted), PTEN (clone 6H2-1;Dako, 1: 300), pSTAT3 (clone F2; Santa Cruz Biotechnology, Dallas, TX, 1:100), VEGF (polyclonal; Millipore, Billerica, MA, 1:1000), and BAF47 (clone 25/BAF47; BD-Biosciences, San Jose, CA, 1:200). Positive controls were used and immunostainings were scored independently by 2 observers (P.V. and A.T-E.) as previously described in the adult series (2) . Cytoplasmic staining for PTEN was considered homogeneously positive if cytoplasmic staining was present in more than 90% of tumor cells.
Molecular Analysis of the SMARCB1 Gene
DNA extraction from formaldehyde-fixed paraffinembedded (FFPE) tumors was performed using the Nucleospin Tissue kit (Macherey-Nagel, Düren, Germany). Six-micrometer-thick dewaxed sections were used for DNA extraction. Samples that underwent decalcification were excluded.
Copy number alterations were searched for using a multiplex ligation-dependent probe amplification (MLPA) assay (Salsa MLPA KIT P258-B1 SMARCB1; MRC Holland, Amsterdam, The Netherlands). Overall, 50 ng of tumor DNAs were used for hybridization, ligation, and amplification according to the manufacturer's instructions in conjunction with a normal control DNA with 2 copies of each exon of the SMARCB1 gene. Two microliters of amplification products were analyzed on an ABI 3130 DNA Analyzer (Applied Biosystems, Foster City, CA). Data analysis was performed using GeneMarker software (SoftGenetics, State College, PA).
Small mutation screenings of each coding exon of the SMARCB1 gene were carried out using Sanger sequencing. Sequences were analyzed on an ABI 3130 DNA sequencer (Applied Biosystems) and further aligned with Seqscape analysis software (Applied Biosystems).
FISH SMARCB1 was carried out on cases with BAF47 immunoexpression loss but without any deletion in the SMARCB1 gene using MLPA analysis. FISH procedures were performed as previously described. Copy number abnormalities were assessed on 100 nuclei by 2 independent observers.
Statistical Analysis
We provide the mean and median values and frequency (percentages) for the description of continuous and categorical variables, respectively. Histopathological and immunohistochemical data were combined to compute a grading score as previously described (2) . OS was defined as the time in months from the date of diagnosis to death from any cause or to the date of the last follow-up. PFS was defined as the time in months between the diagnosis and the earliest date of disease progression (local and distant), death from any cause if no progression was observed or data cutoff. OS and PFS were estimated using the Kaplan-Meier method and expressed by median with a 95% confidence interval (CI). Survival curves were compared using log-rank test. All variables with p 0.05 observed in univariate analysis were included in the multivariate Cox regression model with stepwise backward elimination to estimate hazard ratio with a 95% CI (except variables that were used to build the grading system when it was introduced in the model). All statistical tests were 2-sided, and p < 0.05 were regarded as significant. Data were analyzed by using PASW Statistics for Windows, Version 20.0 (SPSS Inc., Chicago, IL).
RESULTS
Clinical and Surgical Data
The median age was 12 years (mean ¼ 11.1, range from 2.3 to 17.8 years) with a male predominance (24 M/16 F). This series included 29 skull base and 11 non-skull base chordomas; there were no sacrococcygeal chordomas, and no patient initially presented with metastases at the time of primary diagnosis.
Among the 40 included patients, a total resection of the tumor was initially performed for 4 patients and subtotal resection for 28 patients. In 8 cases, the extent of resection was not available. After total resection, no recurrence was observed at 9 months, 5, 9, and 10 years after diagnosis. Among patients with subtotal resection, 21 patients presented a progression of residual tumor (10 of them died of their disease); 7 patients presented with a stable disease.
Adjuvant Treatment
Radiotherapy was the principal adjuvant treatment performed after a maximal tumor resection. All except 6 patients were irradiated by photon beam therapy (n ¼ 7), proton beam therapy (n ¼ 6), or a combination of photon and proton beam therapy (n ¼ 20). For 1 patient, the type of radiotherapy was unknown. Mean doses of irradiation were 54 Gy (minimum ¼ 50 Gy and maximum ¼ 55.8 Gy) for photon beam therapy, 70.8 Gy (minimum ¼ 66.6 Gy and maximum ¼ 74 Gy) for proton beam therapy, and 69.4 Gy (minimum ¼ 60 Gy and maximum ¼ 76 Gy) for the combination therapy.
Four patients received different protocols of chemotherapy, either in cases of progressive metastatic disease (n ¼ 2) or in cases of initial misdiagnosis (n ¼ 2). Disease control was never obtained, and all patients died some months after the beginning of the treatment.
Histopathological Findings
Of the 40 patients in the clinical study, we obtained sufficient histopathological material for 33 of them. Furthermore, 45 tumors (33 primary and 12 recurrences) were included for histopathological assessment. Of the 33 primary chordomas, 15 (45.5%) were classical, 1 (3.0%) was chondroid, 12 (36.4%) were mixed, and 5 (15.1%) were poorly differentiated (Fig. 1) . In all recurrent chordomas, the histopathological subtype remained unchanged between the first surgery and recurrence. Among the 33 primary chordomas, prominent nucleoli, hemorrhage, apoptosis, necrosis, nuclear pleomorphism, and inflammatory cell infiltrates were present in 6 (18.2%), 7 (21.2%), 11 (33.3%), 14 (42.4%), 20 (60.6%), and 24 (72.7%) of the initial tumors, respectively. Mitotic activity was very low.
Immunohistochemical Findings
Insufficient tumor tissue was available to perform all the immunostains in the 45 tumor samples. Nuclear expression of BAF47 was lost in 4 poorly differentiated chordomas and in 3 classical/mixed chordomas (18.9%). The mean Ki67 labeling index (LI) was 14% (1%-60%) and equal or greater than 6% in 14/24 (58.3%) primary chordomas. p53 nuclear accumulation was present in 18/25 (72%) primary chordomas. The mean p53 LI was 29% (1%-91%) and equal to or greater than 25% in 12 primary chordomas. VEGF was intensely expressed in 94.9% of all tumors (37/39 (Fig. 2 ).
Molecular Analysis of the SMARCB1 Gene
MLPA and sequencing of the 9 exons of the SMARCB1 gene were performed on FFPE samples from 5 BAF47-deficient tumors. Only 1 case displayed a biallelic loss of function of the SMARCB1 gene with complete loss of all exons of the SMARCB1 gene on 1 allele and an intragenic deletion of exons 7-9 on the other allele resulting in a heterozygous deletion of exons 1-6 and a homozygous deletion of exons 7-9. In 2 other cases, MLPA analysis revealed a decrease of the probes hybridized on the SMARCB1 gene, including 1 case with a very small decrease of the probes suggesting a loss of at least 1 copy of the gene, but the sample analyzed contained a low fraction of tumor cells. No alteration was detected in the SMARCB1 gene in 1 case, but it could be hypothesized that the fraction of tumor cells was too small and below the sensitivity rate of the MLPA. In that last case, no coherent results were obtained due to the poor quality of extracted DNA from the FFPE sample. FISH analysis of these 2 latter cases was also not contributory due to insufficient number of tumor cells.
Follow-up and Survival Analysis
The OS was 66.6% and 58.6% at 5 and 10 years, respectively, and the PFS was 55.7% and 52% at 5 and 10 years, respectively. After a median follow-up of 5.3 years (min 0.1 years to max 22.3 years), 9 patients (22.5%) were in complete remission and 16 had a stable disease (40%). Fifteen patients (37.5%) died from their disease after a median evolution of 2.3 years (from 0.14 to 5 years). Three patients developed metastasis during follow-up. No recurrence was observed after complete resection. For the others, disease progression occurred earlier after a treatment by surgery alone (mean 453 days) than after an association of surgery and radiotherapy (mean 769 days). The prognosis was better in case of total resection compared to subtotal resection (p ¼ 0.04 for both OS and PFS, log-rank; Table) . We observed a better 5-year PFS for skull base chordomas compared to the others (p ¼ 0.01 log-rank; Table) . Prognostic factors correlated with OS and PFS in univariate and multivariate analyses are listed in the Table.
Grading System
As previously described, histopathological and immunohistochemical parameters were combined to establish a grading system (2): Ki67 LI !6%, p53 LI !25%, presence of a poorly differentiated component, significantly abundant necrosis (!3% of the tumor surface), prominent nucleoli or apoptosis significantly observed (!3% of the tumor cells) or mitoses in more than 3/10 HPF were scored 1, absence of these criteria was scored 0. The sum of these criteria defined a score. The low-(scores 0-3) and high-grade (scores 4-7) groups included 17 and 14 tumors, respectively. Two chordomas were excluded from the grading system due to missing data. The classification into 2 groups has proved to be significantly correlated with PFS and OS (Table; Fig. 3 ).
DISCUSSION
Our results agree with those previously published, as classical chordoma is the most frequent subtype in children, followed by pure chondroid chordoma. Poorly differentiated chordomas (46/222, 20.7%), including dedifferentiated chordomas (12/222, 5.4%), and "atypical" forms (34/222, 15.3%), including epithelioid or solid forms (12 cases), have also been described (3-35) but this histopathological subtype is not included in the 2014 WHO classification of tumors of soft tissue and bone (3, 5, 12, 36, 37) . In our series, a poorly differentiated component represented a significant prognostic factor in terms of PFS and OS as previously assumed (2, 36) (Table) .
Among other histopathological parameters, we observed that nuclear pleomorphism, necrosis, and apoptosis were significantly correlated to OS and PFS (Table) . The poorer prognostic value of nuclear pleomorphism and necrosis had previously been described in adults (2) . However, apoptosis correlated with a shorter survival in our series, contrary to previous studies (2) . Ki67 LI remains a controversial prognostic factor in the literature (3). Our results along with those obtained in a previous study indicate that Ki67 LI is higher in pediatric chordomas than in adult cases (2) . We also observed a higher p53 LI with no prognostic significance, as opposed to other adult and pediatric studies (2) . Finally, loss of E-cadherin expression significantly correlated with a better OS (p ¼ 0.03, log-rank; Table) , according to a previous smaller series (2) . Loss of BAF47 (SMARCB1) immunoexpression represents a powerful prognostic factor in pediatric chordomas. Originally described in atypical teratoid and rhabdoid tumors, alterations of SMARCB1 gene were also described in chordomas and correlated with more aggressive behavior (38) (39) (40) . The mean age of previously reported patients with BAF47-deficient chordomas was 6.9 years (1-17 years) (4, 38, 39, 41, 42) . Chordomas were predominantly located within the skull base, and 19/26 cases (73.1%) were poorly differentiated with sarcoma-like features (4, (38) (39) (40) (41) (42) . This loss of expression is due to mutations (38) , or large deletions of the SMARCB1 gene (40, 42) , as observed in 22.6% of cases in our series. Treatments were extremely variable and progression was observed in 13/15 cases (38, (40) (41) (42) . The loss of BAF47 immunoreactivity correlated with a poorer prognosis and death occurred within the first 3 years after the initial presentation in 14/20 children (4, 38, (40) (41) (42) . This poorer prognosis was confirmed in our series (PFS, p < 0.001, log-rank; Table) , and has led to considering BAF47 immunoexpression as a major prognostic factor for pediatric chordomas.
The prognostic value of the histopathological grading system suggested by our team in the adult series has been confirmed by our pediatric series: patients with a low-grade tumor have a significantly better outcome than patients with a high-grade tumor, both in PFS and OS (Table) . Loss of BAF47 immunoexpression was an independent prognostic factor in term of PFS, and it led us to create a prognostic algorithm based on its immunoexpression and data obtained from our grading system (Fig. 4) . Considering the significant impact of radical surgery and histopathological grading on outcome, we infer that patients with low-grade tumors for whom a complete resection has been performed have a low risk of recurrence. For these patients, we wonder if radiotherapy is necessary as the first line of treatment and if it could be postponed and subsequently offered only for recurrent tumors. We further investigated the expression of molecules that may influence the growth and survival of cancer cells and could lead to targeted therapies. Hypoxia-driven VEGF, a major inducer of tumor angiogenesis, was highly expressed in this series (94.9% of chordomas), as well as in the adult series (2) . While EGFR immunolabeling is highly variable in the literature (8%-81%) (2), it was intensely expressed in 47.4% of tumors in our study. These results are in accordance with a previous but small pediatric series (12) . Previous studies have reported partial response to both anti-VEGF (43) and anti-EGFR drugs (2) in adults, and anti-EGFR therapy has been shown to inhibit growth in a patient-derived chordoma xenograft (2); therefore, these drugs could potentially be useful in the treatment of chordomas. We also found pSTAT3 expression in 87.5% of primary pediatric chordomas, that is, higher than in adult studies (2) . Inhibitors of the STAT3 pathway increased the rate of apoptosis in chemoresistant cancer cell lines and decreased the growth rate of chordoma cell lines (2) , so this biomarker could be considered an interesting therapeutic target. Loss of PTEN expression has previously been observed in chordoma samples and is correlated with tumor invasion (44) . In our study, a loss of expression in the majority of chordomas (73.9% of all cases), was demonstrated, concordant with other studies in which PTEN deletion and loss of the PTEN gene were reported (45, 46) . Treatment of chordomas is based on multidisciplinary management, and all authors agree on the fact that surgery is the first step of this treatment (47) (48) (49) (50) . Surgery has 2 aims: to reduce the tumor volume and, if possible, to obtain complete resection, and to keep any residue away from vascular or nervous anatomical structures for adjuvant radiotherapy. Limited data exist on pediatric series due to the small size of cohorts but Ridenour et al observed a tendency for a better OS in case of total resection compared to subtotal resection (n ¼ 35, p ¼ 0.374) (3). In our series, this difference was significant in terms of OS and PFS (p ¼ 0.04, log-rank; Table) . Complete resection of these tumors remains challenging and varies from 0% to 36.4% in the main pediatric studies (22.5% in our series) (3, 47, 49, 51) . High-dose radiotherapy is considered to be the standard treatment after surgery (30, (52) (53) (54) . Limited data are available for children but in a review on intracranial chordomas, the benefit of radiotherapy was clearly established (OS, p ¼ 0.004) (36) . Proton therapy has become the technique of choice (55, 56) because it allows for higher doses of radiation on tumor tissue while sparing adjacent healthy tissue (5, 57, 58) . In our cohort, patients who were irradiated had a better outcome in terms of PFS and OS (p < 0.001, log-rank, Table) , but patients who were not irradiated died rapidly or presented a rapid growth of the tumor. Thus, it is difficult to conclude on the direct consequences of the absence of irradiation of our patients. Considering the high potential for local recurrence of chordomas, the benefits of reirradiation may also have to be evaluated in the case of progressive disease, as is recommended for other pediatric tumors (59) .
In conclusion, our results provide evidence that the aforementioned clinical and histopathological parameters are correlated with prognosis. Our grading system combined with the quality of surgical resection could help in categorizing patients and postponing radiotherapy in low-risk cases. The immunoexpression of biomarkers implicated in targeted therapy (EGFR, VEGF, and STAT3 pathways) could help in the selection of therapeutic strategies among those highly expressed.
